CRDN

Views & Analysis

The lessons that can be learned for the future of drug development from the collaboration and innovation in this space.

Views & Analysis

CRDN wants to break down barriers in communication between rare disease patients, HCPs and industry.

News

Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, drawing on phase 3 data at ESC 2026.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.